Acute myeloid leukaemia accounts for approximately 30% of blood cancers, with an incidence of 30,000 new cases in Europe per year (2,000 in Italy). It is a disease with a severe prognosis, with only 24% of patients surviving at 5 years.
MEN1112 is the first monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics) that acts through an ADCC (Antibody-Dependent Cellular Toxicity) mechanism of action.
The target of MEN1112 is CD157, a protein expressed on leukemic cancer cells (blasts); data showing antitumor effects on cancer cell lines and on leukemic blasts from patients are now available.
The biotechnological process for the production of MEN1112 has been developed at Menarini Biotech in Pomezia. The first in human study in patients with relapsed/refractory acute myeloid leukemia (clinical study ARMY) is ongoing.
VISIT OUR CLINICAL TRIALS DATABASE